Non-Toxic Gel to Treat Vulvovaginal Candidiasis

用于治疗外阴阴道念珠菌病的无毒凝胶

• 批准号: 7051865
• 负责人: Charles J Gauntt
• 金额: $ 11.03万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7051865
• 关键词: Candida; candidiasis; gel; iodine

DESCRIPTION (provided by applicant): The goal of this project is to develop a safe biocidal vaginal gel for treatment of vulvovaginal candidiasis (WC). WC is caused by one of several airborne species of the yeast Candida that are normal inhabitants of humans at several sites, including the vagina. C. albicans has been associated with causing WC in the past, but drug-resistant non-C. albicans spp. are increasingly being identified as the cause of WC. Many of: he non-C. albicans strains are resistant to normal levels of antifungal drugs. As a result, recurrent WC has become an increasingly common and chronic problem, with patients becoming refractory to treatment due to imitations in available therapy. Biomedical Development Corporation (BDC) is evaluating lova gel as a novel, safe, and effective microbicide. lova gel is a broad-spectrum biocide with activity against viruses, bacteria, and yeast, without nducing resistant mutants or allergenicity. The goal of this project is to develop lova vaginal gel as a treatment for vulvovaginal candidiasis. BDC will execute the following specific aims: Specific Aim 1: Formulate lova Gel Formulations for Use in Treating Vulvovaginal Candidiasis Specific Aim 2: Demonstrate Safety of lova Gel Formulations Specific Aim 3: Demonstrate Effectiveness of lova Gel Formulations in Killing Planktonic Candida spp. Specific Aim 4: Demonstrate that lova Gel is Effective in Eradicating a Persistent Candida albicans Vaginal Infection in Rats , Relevance to Public Health: Vaginitis is the most common gynecologic diagnosis in primary care globally, affecting an estimated 1 billion women each year. WC accounts for 30-45% of vaginitis, and approximately 75% of premenopausal women will have at least one episode of WC. Among premenopausal women, 70- 75% will have at least one episode of WC and half of all college women will, by age 25, have had one episode of WC diagnosed by a physician. Annual costs for treating WC in the U.S. are estimated at $1.8 billion.

描述（由申请人提供）：该项目的目的是开发安全的杀生物性阴道凝胶来治疗外阴阴道念珠菌病（WC）。 WC是由酵母念珠菌的几种空气传播物种之一引起的，它们是包括阴道在内的多个部位的正常居民。白色念珠菌过去一直在引起WC，但耐药的非C。白色疾病属。越来越多地被确定为WC的原因。许多：he non-c。白色疾病菌株对正常水平的抗真菌药物具有抗性。结果，复发性WC已成为越来越普遍且慢性的问题，由于可用治疗中的模仿，患者对治疗产生了难治性。生物医学开发公司（BDC）正在评估Lova凝胶是一种新颖，安全且有效的杀菌剂。 Lova凝胶是一种具有针对病毒，细菌和酵母的活性的广谱杀菌剂，而无需抗性突变体或过敏反应。该项目的目的是开发Lova阴道凝胶作为外阴阴道念珠菌病的治疗方法。 BDC将执行以下特定目的：特定目的1：制定LOVA凝胶配方，用于治疗外阴阴道念珠菌病的特定目的2：证明LOVA凝胶配方的安全性特定目标3：证明LOVA凝胶配方在杀死Planktonic Candida spp中的有效性。特定目的4：证明LOVA凝胶可以有效地消除大鼠白色念珠菌阴道感染的持续性念珠菌，与公共卫生有关：阴道炎是全球初级保健中最常见的妇科诊断，每年影响10亿女性。 WC占阴道炎的30-45％，大约75％的绝经前妇女将至少有一个WC发作。在绝经前妇女中，有70-75％的妇女将至少有一个WC的一集，而到25岁的大学妇女中有一半将被医生诊断出一集WC。美国治疗WC的年度费用估计为18亿美元。